# Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

> **NCT07079579** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Renal Anemia in Non-dialysis Chronic Kidney Disease

## Interventions

- **DRUG:** Enarodustat 2mg
- **DRUG:** Enarodustat 3mg
- **DRUG:** Enarodustat 4mg

## Key facts

- **NCT ID:** NCT07079579
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07079579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07079579, "Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07079579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*